The rate of confirmed cases of the “externalized conductor” phenomenon with St. Jude Medical’s no-longer-marketed, silicone-insulated Riata implantable defibrillator lead climbed to 0.3% as of Feb. 29, according to the firm’s latest cardiac rhythm management product performance report, released May 1.
The rate was 0.17% as of Dec. 31 and 0.1% of last November, when St. Jude issued an advisory for...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?